About sanbio co ltd - SNBIF
SanBio Co., Ltd. engages in the development, production and sale of regenerative cells medicines. It provides regenerative therapies for neurological disorders that include stroke, traumatic brain injury, eye diseases, and Parkinson's disease. The company was founded on February 27, 2013 and is headquartered in Tokyo, Japan.
SNBIF At a Glance
SanBio Co., Ltd.
St. Luke Tower, 32/F
Tokyo, Tokyo 104-0044
| Phone | 81-3-6264-3481 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -18,921,728.72 | |
| Sector | Health Technology | Employees | 29 | |
| Fiscal Year-end | 01 / 2026 | |||
| View SEC Filings |
SNBIF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 28.968 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -13.204 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.008 |
SNBIF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -652,473.404 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SNBIF Liquidity
| Current Ratio | 4.556 |
| Quick Ratio | 4.556 |
| Cash Ratio | 3.991 |
SNBIF Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -66.636 |
| Return on Equity | -124.126 |
| Return on Total Capital | -135.654 |
| Return on Invested Capital | -111.184 |
SNBIF Capital Structure
| Total Debt to Total Equity | 22.519 |
| Total Debt to Total Capital | 18.38 |
| Total Debt to Total Assets | 11.516 |
| Long-Term Debt to Equity | 7.317 |
| Long-Term Debt to Total Capital | 5.972 |